Keys to the program include:
“PBMCs are the raw material from which many mobile treatments can be derived and it makes sense to keep and store their mobiles healthy before they worsen with ageing, and in anticipation of the immediate long-term progression of this new medical science,” said Mr Schulz. . Peter Choo, President of CytoMed. We own our cGMP lab to ensure quality and load control, and we have proprietary technologies to manufacture clinical-grade CAR-T mobiles as add-on treatments if proposed by the patient’s doctor without choice. Doctors were born to encourage patients to keep their cell phones. pre-birth competitive chemotherapy.
About CytoMed Therapeutics Limited (CytoMed) Incorporated in 2018, CytoMed was spun off from the Agency for Science, Technology and Research (A*STAR), Singapore’s leading public sector research and progression agency. It is a biopharmaceutical company that aims to leverage its patented and licensed technologies, namely iPSC-derived gamma delta T cells and Natural Killer gamma delta T cells, to create novel cell-based allogeneic immunotherapies for the treatment of human cancers. The advance of new technologies has been favoured by the clinical good fortune of existing CAR-T treatments in the treatment of haematological malignancies, as well as by the existing clinical limitations and publicity required by situations such as the extrapolation of the CAR-T precept to treatment. For more information, visit www. cytomed. sg and follow us on Twitter (“X”) @CytomedSG, LinkedIn and Facebook.
Forward-Looking Statements This press release includes forward-looking statements as set forth in the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements regarding long-term plans, objectives, goals, strategies, opportunities or functions, as well as as underlying assumptions and other statements. which are not statements of ancient facts. When the Company uses words such as “may”, “will”, “intend”, “should”, “believe”, “expect”, “anticipate”, “plan”, “estimate” or similar expressions that do not relate only to the old material. account, makes forward-looking statements. Forward-looking statements are not promises of long-term functionality and involve dangers and uncertainties that could possibly cause actual effects to differ materially from the Company’s expectations discussed in the forward-looking statements. These statements are subject to uncertainties and dangers, including the following: the Company’s plans to expand and commercialize its applicant products; the initiation, timing, progress and effects of the Company’s existing and long-term preclinical studies and clinical trials and the Company’s R&D programs; the Company’s expectations related to the impact of the current COVID-19 pandemic on its business, industry and economy; the Company’s estimates related to expenses, long-term revenues, capital needs and additional financing needs; the Company’s ability to obtain or license other product applicants on moderate terms; the Company’s ability to identify and maintain collaborations and/or discharge additional financing and assumptions underlying or related to any of the foregoing hazards and other hazards contained in the reports filed by the Company with the SEC. For those and other reasons, investors are cautioned not to place undue reliance on the forward-looking statements contained in this press release. Additional points are discussed in the Company’s filings with the SEC, which can be found at www. sec. gov. The Company undertakes no legal responsibility to publicly revise such forward-looking statements to reflect occasions or events occurring after the date hereof.
CytoMed Therapeuticsenquiry@cytomed. sgAttn: Ms. Lynne Ng, Legal Consultant